Gland Pharma · NSE: GLAND · BSE: 543245
Q3 FY23 results · Oct–Dec 2022
Gland Pharma reported revenue from operations of ₹938.29 crore (down 11.8% from Q3 FY22) and net profit of ₹231.95 crore (down 15.0% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 938.29 | 1,063.33 | −11.8% | 1,044.40 | −10.2% |
| Other income | 61.51 | 45.67 | +34.7% | 65.62 | −6.3% |
| Total income | 999.80 | 1,108.99 | −9.8% | 1,110.03 | −9.9% |
| Profit before tax | 310.85 | 365.56 | −15.0% | 324.08 | −4.1% |
| Net profit for the period | 231.95 | 273.03 | −15.0% | 241.24 | −3.9% |
| EPS, basic (₹) | 14.08 | 16.62 | −15.3% | 14.65 | −3.9% |
| Net margin (%) | 24.7 | 25.7 | 23.1 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 925.90 | 1,063.33 | −12.9% | 1,048.31 | −11.7% |
| Other income | 61.51 | 45.67 | +34.7% | 65.62 | −6.3% |
| Total income | 987.41 | 1,108.99 | −11.0% | 1,113.93 | −11.4% |
| Profit before tax | 305.24 | 365.92 | −16.6% | 322.47 | −5.3% |
| Net profit for the period | 227.54 | 273.38 | −16.8% | 239.63 | −5.0% |
| EPS, basic (₹) | 13.82 | 16.64 | −16.9% | 14.55 | −5.0% |
| Net margin (%) | 24.6 | 25.7 | 22.9 |
Consolidated
- Filed with BSE
- 24 Jan 2023, 11:43 IST
- Board meeting
- 23 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jan 2023, 11:43 IST
- Board meeting
- 23 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE